Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile.
Journal
Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
04
08
2021
accepted:
23
02
2022
entrez:
2
4
2022
pubmed:
3
4
2022
medline:
6
4
2022
Statut:
ppublish
Résumé
SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (n = 53) and BNT162b2 (n = 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (n = 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246-252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
Identifiants
pubmed: 35365787
doi: 10.1038/s41564-022-01092-1
pii: 10.1038/s41564-022-01092-1
doi:
Substances chimiques
Antibodies, Neutralizing
0
Membrane Glycoproteins
0
Spike Glycoprotein, Coronavirus
0
Viral Envelope Proteins
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
524-529Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021).
doi: 10.1038/s41579-021-00573-0
Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773 (2021).
doi: 10.1038/s41576-021-00408-x
Tracking SARS-CoV-2 Variants (WHO, 2021).
Romero, P. E. et al. The emergence of Sars-CoV-2 variant Lambda (C.37) in South America. Microbiol. Spectr. 9, e0078921 (2021).
doi: 10.1128/Spectrum.00789-21
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
doi: 10.1038/s41591-021-01377-8
Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423–4428 (2021).
doi: 10.1016/j.vaccine.2021.05.063
Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52–e61 (2022).
doi: 10.1016/S2666-5247(21)00267-6
Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).
doi: 10.1126/science.abm3425
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032–2040 (2021).
doi: 10.1038/s41591-021-01540-1
Mallapaty, S. China’s COVID vaccines have been crucial – now immunity is waning. Nature 598, 398–399 (2021).
doi: 10.1038/d41586-021-02796-w
Beltrán-Pavez, C. et al. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Sci. Adv. 7, eabe6855 (2021).
doi: 10.1126/sciadv.abe6855
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 e4 (2021).
doi: 10.1016/j.chom.2021.01.014
Motozono, C. et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29, 1124–1136 e11 (2021).
doi: 10.1016/j.chom.2021.06.006
Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020).
doi: 10.7554/eLife.61312
McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347.e16 (2021).
doi: 10.1016/j.cell.2021.03.028
González-Puelma, J. et al. Mutation in a SARS-CoV-2 haplotype from sub-Antarctic Chile reveals new insights into the Spike’s dynamics. Viruses 13, 883 (2021).
doi: 10.3390/v13050883
Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739–751.e8 (2020).
doi: 10.1016/j.cell.2020.09.032
Mansbach, R. A. et al. The SARS-CoV-2 spike variant D614G favors an open conformational state. Sci. Adv. 7, eabf3671 (2021).
doi: 10.1126/sciadv.abf3671
Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812–827.e19 (2020).
doi: 10.1016/j.cell.2020.06.043
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Liu, C. et al. The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET. Structure 28, 1218–1224 e4 (2020).
doi: 10.1016/j.str.2020.10.001
Gupta, D. et al. Inactivation of SARS-CoV-2 by beta-propiolactone causes aggregation of viral particles and loss of antigenic potential. Virus Res. 305, 198555 (2021).
doi: 10.1016/j.virusres.2021.198555
Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021).
doi: 10.1016/S0140-6736(21)00947-8
Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875–884 (2021).
doi: 10.1056/NEJMoa2107715
Wang, M. et al. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerg. Microbes Infect. 11, 18–29 (2022).
doi: 10.1080/22221751.2021.2008775